Drugs
Researchers at the University of California, Davis Cancer Center have developed a novel peptide, LLP2A, that binds to the surface of leukemia and lymphoma cells with high affinity and specificity. The peptide demonstrates remarkable potential as a tool for imaging tumors and delivering anti-cancer drugs. In the Nature Chemical Biology
Drugs
Researchers have discovered a new potential approach for treating human cancers, focusing on the regulation of microRNAs (miRNAs) through epigenetic processes. A study published in Cancer Cell reveals that agents known to affect gene expression can also influence the function of miRNAs, which may serve as tumor suppressors in normal
Drugs
Research from Turkey, Italy, and the United States has shed light on the impact of statins on diabetic patients, particularly in relation to coronary collateral development. A study in the American Journal of Cardiology found that statin treatment and stable angina pectoris are associated with better coronary collateral development in
Drugs
Research from scientists in Australia, Japan, and the United States has shed new light on retinopathy, a leading cause of vision loss worldwide. Recent studies have focused on understanding the underlying mechanisms of angiogenesis, the formation of new blood vessels, which is a hallmark of retinopathy. Three studies have made
Drugs
Pregnant women with Type 1 diabetes and microalbuminuria face a higher risk of preterm delivery. Researchers have investigated the impact of early antihypertensive treatment with methyldopa on this risk. In a study published in Diabetic Medicine, investigators found that introducing early antihypertensive treatment with methyldopa resulted in a significant reduction
Drugs
Recent research has identified a novel therapeutic approach for heritable breast cancer, leveraging the transcriptional activation of PPAR gamma by Lovastatin and Rosiglitazone. According to a study published in the International Journal of Cancer, the activation of PPAR gamma by these compounds induces PTEN expression, a tumor suppressor gene that
Drugs
Researchers at the University of Pittsburgh Medical Center are making significant contributions to the medical field, shedding light on the effectiveness of various treatments for different diseases. According to recent studies, the center's researchers have discovered that resected non-small cell lung cancer (NSCLC) patients exhibit extreme chemotherapy resistance,
Drugs
Recent studies from the Catholic University of Korea have shed light on the mechanisms underlying rheumatoid arthritis (RA) angiogenesis and the formation of silicotic nodules in rats. In the first study, researchers investigated the role of interleukin-18 (IL-18) in driving angiogenesis in RA synovial fibroblasts. They found that IL-18 induces
Drugs
In a significant breakthrough in cancer treatment, Alfacell Corporation's Onconase (ranpirnase) has been found to induce apoptosis in apoptosis-resistant non-small cell lung cancer (NSCLC) cells. According to a study presented at the 14th Annual Meeting of the International Society for Magnetic Resonance in Medicine (ISMRM), Onconase causes significant
Drugs
According to research from the United States, specific overexpression of the antiapoptotic molecule Bcl-2 in normal cells inhibited radiation-induced apoptosis, thereby reducing radiation-induced toxicity in normal cells. At the M.D. Anderson Cancer Center, researchers constructed a Bcl-2 expression plasmid with a minimal promoter regulated by multiple wild-type p53 DNA-binding
Drugs
Clinical trials evaluating the systemic administration of OGX-011, an antisense drug, in combination with standard chemotherapy agents, have yielded promising results in patients with non-small cell lung cancer (NSCLC). The phase I study, conducted by OncoGenex Technologies Inc. in collaboration with Isis Pharmaceuticals Inc., demonstrated a 1-year survival rate of
Drugs
Human Genome Sciences, Inc., (HGSI) has announced promising 12-week interim results from a phase IIb clinical trial evaluating the efficacy and safety of Albuferon (albumin-interferon alpha 2b) in combination with ribavirin in patients with genotype 1 chronic hepatitis C (HCV) who are naive to interferon alpha-based treatment regimens. The results
